Calciphylaxis is not uncommon in individuals with kidney disease. Review the incidence, prevalence, risk factors, and diagnostic criteria for calciphylaxis. Discussion covers skin lesions in calciphylaxis and emerging treatment options to halt the disease’s progression.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 5/5/2023.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: There are no Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: Sagar Nigwekar, MD – Consultant for Epizon Pharma, Inc., Fresenius Medical Care Renal Therapies Group, Laboratoris Sanifit, Guidepoint; Grant for research work from Hope Pharma, Laboratoris Sanifit
There are no other speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: The American Nephrology Nurses Association (ANNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.
ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: Upon completion of this activity, the learner will be able to plan care for patients with calciphylaxis based on the best evidence.
Co-Director, Kidney Research Center,
Massachusetts General Hospital